321 related articles for article (PubMed ID: 24273759)
1. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
2. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
[TBL] [Abstract][Full Text] [Related]
3. The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.
Glowacki S; Synowiec E; Blasiak J
Int J Mol Sci; 2013 Aug; 14(8):16348-64. PubMed ID: 23965958
[TBL] [Abstract][Full Text] [Related]
4. The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia.
El-Tanani M; Nsairat H; Matalka II; Lee YF; Rizzo M; Aljabali AA; Mishra V; Mishra Y; Hromić-Jahjefendić A; Tambuwala MM
Pathol Res Pract; 2024 Feb; 254():155161. PubMed ID: 38280275
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
Kaehler M; Cascorbi I
Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
[TBL] [Abstract][Full Text] [Related]
7. ACY-1215 suppresses the proliferation and induces apoptosis of chronic myeloid leukemia cells via the ROS/PTEN/Akt pathway.
Qin Y; Liang Y; Jiang G; Peng Y; Feng W
Cell Stress Chaperones; 2022 Jul; 27(4):383-396. PubMed ID: 35674911
[TBL] [Abstract][Full Text] [Related]
8. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
9. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract][Full Text] [Related]
10. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy.
Rodriguez J; Iniguez A; Jena N; Tata P; Liu ZY; Lander AD; Lowengrub J; Van Etten RA
Elife; 2023 Apr; 12():. PubMed ID: 37115622
[TBL] [Abstract][Full Text] [Related]
11. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
Gonzalez MA; Olivas IM; Bencomo-Alvarez AE; Rubio AJ; Barreto-Vargas C; Lopez JL; Dang SK; Solecki JP; McCall E; Astudillo G; Velazquez VV; Schenkel K; Reffell K; Perkins M; Nguyen N; Apaflo JN; Alvidrez E; Young JE; Lara JJ; Yan D; Senina A; Ahmann J; Varley KE; Mason CC; Eide CA; Druker BJ; Nurunnabi M; Padilla O; Bajpeyi S; Eiring AM
Clin Transl Med; 2022 Dec; 12(12):e1146. PubMed ID: 36536477
[TBL] [Abstract][Full Text] [Related]
12. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia.
Short NJ; Senapati J; Jabbour E
Curr Hematol Malig Rep; 2023 Dec; 18(6):234-242. PubMed ID: 37651057
[TBL] [Abstract][Full Text] [Related]
13. Role of miRNAs to control the progression of Chronic Myeloid Leukemia by their expression levels.
Bansal M; Ansari S; Verma M
Med Oncol; 2024 Jan; 41(2):55. PubMed ID: 38216843
[TBL] [Abstract][Full Text] [Related]
14. The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia.
Deręgowska A; Pępek M; Solarska I; Machnicki MM; Pruszczyk K; Dudziński M; Niesiobędzka-Krężel J; Seferyńska I; Sawicki W; Wnuk M; Stokłosa T
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7103-7112. PubMed ID: 36871092
[TBL] [Abstract][Full Text] [Related]
15. FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.
Takeda K; Ohta S; Nagao M; Kobayashi E; Tago K; Funakoshi-Tago M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612503
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.
Vicente ATS; Salvador JAR
Expert Opin Ther Pat; 2023; 33(6):397-420. PubMed ID: 37494069
[TBL] [Abstract][Full Text] [Related]
17. Role of epigenetics in chronic myeloid leukemia.
Machova Polakova K; Koblihova J; Stopka T
Curr Hematol Malig Rep; 2013 Mar; 8(1):28-36. PubMed ID: 23296408
[TBL] [Abstract][Full Text] [Related]
18. MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia.
Arya D; Sachithanandan SP; Ross C; Palakodeti D; Li S; Krishna S
Cell Death Dis; 2017 Jan; 8(1):e2547. PubMed ID: 28079885
[TBL] [Abstract][Full Text] [Related]
19. Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Shibata N; Ohoka N; Tsuji G; Demizu Y; Miyawaza K; Ui-Tei K; Akiyama T; Naito M
Oncogene; 2020 May; 39(19):3867-3878. PubMed ID: 32203161
[TBL] [Abstract][Full Text] [Related]
20. [Novel therapeutic strategy for targeting chronic myeloid leukemia stem cells via IRAK1/4 inhibition].
Tanaka Y; Kitamura T
Rinsho Ketsueki; 2023; 64(9):1007-1018. PubMed ID: 37793857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
